NPT200-11 是一种口服生物利用度和脑穿透性 ASYN 错误折叠和聚集抑制剂。 NPT200-11 可用于突触核蛋白病的潜在病理学研究，包括帕金森病 (PD)、路易体痴呆 (DLB) 和多系统萎缩 (MSA)。

NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).

In the Line 61 transgenic mouse model overexpressing human wild type ASYN, NPT200-11 (5 mg/kg; i.p.) results in a time-dependent and progressive reduction in retinal ASYN pathology. NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function[1].

2227057-23-8

NPT200-11

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years